机构:[1]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 17 South Panjiayuan Lane, Beijing 100021, People’s Republic of China[2]Department of Oncology, First Afliated Hospital of Xinxiang Medical University, 88 Jiankang Road, Weihui 453100, Henan, People’s Republic of China[3]Department of Radiation Oncology, Afliated Hospital of Hebei University, Baoding 071000, People’s Republic of China河北大学附属医院[4]Department of Oncology, Tengzhou Central People’s Hospital, Tengzhou 277599, People’s Republic of China[5]Department of Radiation Oncology, The First Afliated Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, People’s Republic of China河南省肿瘤医院[6]Department of Radiation Oncology, Anyang Tumor Hospital, The Fourth Afliated Hospital of Henan University of Science and Technology, Anyang 455000, People’s Republic of China[7]Department of Radiation Oncology, The Afliated Hospital of Inner Mongolia Medical University, Tongdao Road, Hohhot 10050, Inner Mongolia, People’s Republic of China[8]Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, People’s Republic of China河北医科大学第四医院[9]Department of Radiation Oncology, Fujian Cancer Hospital/Fujian Medical University Cancer Hospital, Fuzhou 350014, People’s Republic of China[10]Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing Dongcheng District, Beijing, People’s Republic of China[11]Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital/National Clinical Research Center for Cancer, Tianjin 300060, People’s Republic of China[12]Department of Radiation Oncology, Beijing Hospital, National Center of Gerontology, Beijing 100730, People’s Republic of China[13]Department of Radiation Oncology, The First Afliated Hospital of Nanjing Medical University, Nanjing 210029, People’s Republic of China[14]Department of Radiation Oncology, Afliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450008, People’s Republic of China河南省肿瘤医院[15]Department of Radiation Oncology, The Seventh Medical Center of PLA General Hospital, Beijing 100700, People’s Republic of China[16]Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, People’s Republic of China
Purpose To investigate the interobserver variability (IOV) in target volume delineation of definitive radiotherapy for thoracic esophageal cancer (TEC) among cancer centers in China, and ultimately improve contouring consistency as much as possible to lay the foundation for multi-center prospective studies. Methods Sixteen cancer centers throughout China participated in this study. In Phase 1, three suitable cases with upper, middle, and lower TEC were chosen, and participants were asked to contour a group of gross tumor volume (GTV-T), nodal gross tumor volume (GTV-N) and clinical target volume (CTV) for each case based on their routine experience. In Phase 2, the same clinicians were instructed to follow a contouring protocol to re-contour another group of target volume. The variation of the target volume was analyzed and quantified using dice similarity coefficient (DSC). Results Sixteen clinicians provided routine volumes, whereas ten provided both routine and protocol volumes for each case. The IOV of routine GTV-N was the most striking in all cases, with the smallest DSC of 0.37 (95% CI 0.32-0.42), followed by CTV, whereas GTV-T showed high consistency. After following the protocol, the smallest DSC of GTV-N was improved to 0.64 (95% CI 0.45-0.83, P = 0.005) but the DSC of GTV-T and CTV remained constant in most cases. Conclusion Variability in target volume delineation was observed, but it could be significantly reduced and controlled using mandatory interventions.
基金:
Beijing Hope Run Special Fund of Cancer Foundation of China [LC2016L04]
基金编号:LC2016L04
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类|2 区医学
小类|2 区核医学3 区肿瘤学
最新[2025]版:
大类|2 区医学
小类|2 区核医学3 区肿瘤学
JCR分区:
出版当年[2021]版:
Q2ONCOLOGYQ2RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
最新[2023]版:
Q1RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGINGQ2ONCOLOGY
第一作者机构:[1]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 17 South Panjiayuan Lane, Beijing 100021, People’s Republic of China
通讯作者:
推荐引用方式(GB/T 7714):
Chang Xiao,Deng Wei,Wang Xin,et al.Interobserver variability in target volume delineation in definitive radiotherapy for thoracic esophageal cancer: a multi-center study from China[J].RADIATION ONCOLOGY.2021,16(1):102.doi:10.1186/s13014-020-01691-4.
APA:
Chang, Xiao,Deng, Wei,Wang, Xin,Zhou, Zongmei,Yang, Jun...&Xiao, Zefen.(2021).Interobserver variability in target volume delineation in definitive radiotherapy for thoracic esophageal cancer: a multi-center study from China.RADIATION ONCOLOGY,16,(1)
MLA:
Chang, Xiao,et al."Interobserver variability in target volume delineation in definitive radiotherapy for thoracic esophageal cancer: a multi-center study from China".RADIATION ONCOLOGY 16..1(2021):102